India's Alembic Pharma up on US FDA approval for cancer product

Alembic Pharmaceuticals

01/04/2024 08:33

** Shares of Alembic Pharmaceuticals  ALEM.NS  rise as much
as 4.1% to 1,024.85 rupees, last up 3.8%
    ** Co gets U.S. FDA approval during the qtr ended March 31
for Ribociclib tablets used in the treatment of metastatic
breast cancer
    ** ALEM on track for fourth straight session of gains; it
fell 3.4% in March, snapping a four-month winning run
    ** Thirteen analysts covering the stock on average have a
"hold" rating; median PT is 897.50 rupees - LSEG data
    ** Stock up ~35% YTD


 (Reporting by Dimpal Gulwani in Bengaluru)
 ((dimpal.gulwani@thomsonreuters.com))